Artemether-lumefantrine versus artemisinin-naphthoquine in Papua New Guinean children with uncomplicated malaria: A six months post-treatment follow-up study
MetadataShow full item record
Background: In a recent trial of artemisinin-naphthoquine (artemisinin-NQ) and artemether-lumefantrine (AM-LM) therapy in young children from Papua New Guinea (PNG), there were no treatment failures in artemisinin-NQ-treated children with Plasmodium falciparum or Plasmodium vivax compared with 2.2% and 30.0%, respectively, in AM-LM-treated children during 42 days of follow-up. To determine whether, consistent with the long elimination half-life of NQ, this difference in efficacy would be more durable, clinical episodes of malaria were assessed in a subset of trial patients followed for six months post-treatment. Methods: For children completing trial procedures and who were assessable at six months, all within-trial and subsequent clinical malaria episodes were ascertained, the latter by clinic attendances and/or review of hand-held health records. Presentations with non-malarial illness were also recorded. Differences between allocated treatments for pre-specified endpoints were determined using Kaplan-Meier survival analysis. Results: Of 247 children who were followed to Day 42, 176 (71.3%) were included in the present sub-study, 87 allocated to AM-LM and 89 to artemisinin-NQ. Twenty children in the AM-LM group (32.8%) had a first episode of clinical malaria within six months compared with 10 (16.4%) in the artemisinin-NQ group (P=0.033, log rank test). The median (interquartile range) time to first episode of clinical malaria was 64 (50-146) vs 116 (77-130) days, respectively (P=0.20). There were no between-group differences in the incidence of first presentation with non-malarial illness (P=0.31). Conclusions: The greater effectiveness of artemisinin-NQ over conventional AM-LM extends to at least six months post-treatment for clinical malaria but not non-malarial illness. Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12610000913077.
This open access article is distributed under the Creative Commons license https://creativecommons.org/licenses/by/4.0/
Showing items related by title, author, creator and subject.
Artemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized TrialLaman, M.; Moore, Brioni; Benjamin, J.; Yadi, G.; Bona, C.; Warrel, J.; Kattenberg, J.; Koleala, T.; Manning, L.; Kasian, B.; Robinson, L.; Sambale, N.; Lorry, L.; Karl, S.; Davis, W.; Rosanas-Urgell, A.; Mueller, I.; Siba, P.; Betuela, I.; Davis, T. (2014)© 2014 Laman et al. Artemisinin combination therapies (ACTs) with broad efficacy are needed where multiple Plasmodium species are transmitted, especially in children, who bear the brunt of infection in endemic areas. In ...
Joshua, Isaac B. (2003)Malaria is more prevalent today and the death toll is on the increase annually. It is one of the leading causes of morbidity and mortality worldwide and most of these deaths are in the poorest regions of the world. About ...
Gametocyte clearance kinetics determined by quantitative magnetic fractionation in Melanesian children with uncomplicated malaria treated with artemisinin combination therapyKarl, S.; Laman, M.; Moore, Brioni; Benjamin, J.; Koleala, T.; Ibam, C.; Kasian, B.; Siba, P.; Waltmann, A.; Mueller, I.; Woodward, R.; St Pierre, T.; Davis, T. (2015)Copyright © 2015, American Society for Microbiology. All Rights Reserved.Quantitative magnetic fractionation and a published mathematical model were used to characterize between-treatment differences in gametocyte density ...